Pharmacokinetics of 4-[4"-(2",2",6",6"-tetramethyl-1"-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin in mice bearing sarcoma 180.
OBJECTIVE
To study the pharmacokinetics of 4-[4"-(2",2",6",6"-tetramethyl- 1"-piperindyloxy) amino]-4'-demethylepipodophyllotoxin (GP-7) in mice bearing sarcoma 180.


METHODS
Using HPLC with a uv detector at 285 nm.


RESULTS
The plasma concentration-time course of GP-7 in mice was best fitted to a 2-compartment open modle after iv 20, 60 mg.kg-1. At both doses the plasma T1/2 beta was around 40 min. The highest concentration was found in liver and lung. The level of GP-7 was higher in tumor than in kidney, spleen, and bone marrow after ip 20 mg.kg-1 for 10 d. Urinary excretion of GP-7 as unchanged drug accounted for about 20% of the administered doses 72 h after injection.


CONCLUSIONS
GP-7 disappeared more slowly from the plasma of mice bearing sarcoma 180, distributed extensively over the tissues and was partially excreted from urine. The concentrition of GP-7 in tumor was higher.
Jia
Z P
ZP
Department of Pharmacy, Lanzhou General Hospital, PLA, China.
Xie
J W
JW
Xie
T Q
TQ
D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000652:urine; D005260:Female; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D011034:Podophyllotoxin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000652:urine; D012510:Sarcoma 180 / Q000378:metabolism*; D014018:Tissue Distribution
D000970:Antineoplastic Agents; C071346:GP 7; D011034:Podophyllotoxin